Abstract
Feline injection-site sarcomas are malignant skin tumours with a high local recurrence rate, ranging from 14% to 28%. The treatment of feline injection-site sarcomas includes radical surgery, radiotherapy and/or chemotherapy. In our previous study it has been demonstrated that doxorubicin conjugated to glutathione-stabilized gold nanoparticles (Au-GSH-Dox) has higher cytotoxic effects than free doxorubicin for feline fibrosarcoma cell lines with high glycoprotein P activity (FFS1, FFS3). The aim of the present study was to assess the effectiveness of intratumoural injection of Au-GSH-Dox on the growth of tumours from the FFS1 and FFS3 cell lines on chick embryo chorioallantoic membrane. This model has been utilized both in human and veterinary medicine for preclinical oncological studies. The influence of intratumoural injections of Au-GSH-Dox, glutathione-stabilized gold nanoparticles and doxorubicin alone on the Ki-67 proliferation marker was also checked. We demonstrated that the volume ratio of tumours from the FFS1 and FFS3 cell lines was significantly (p < 0.01) decreased after a single intratumoural injection of Au-GSH-Dox, which confirms the positive results of in vitro studies and indicates that Au-GSH-Dox may be a potent new therapeutic agent for feline injection-site sarcomas.
Highlights
Feline injection-site sarcomas (FISS) are malignant skin tumours with a high local recurrence rate (14%–28%) [1] and metastasis risk ranging from 10% to 28% [2]
In previously performed in vitro studies we studies we have that doxorubicin glutathione gold (Au-GSH-Dox) nanoparticles have proven thatproven doxorubicin conjugated toconjugated glutathionetostabilized goldstabilized nanoparticles (Au-GSH-Dox) has a higher for felinecell fibrosarcoma lineswith (FFS1, FFS3)
Zhang and collaborators demonstrated that intratumoural injection of ultra-small gold nanoparticles conjugated to doxorubicin (Au-Dox) for accessible skin cancers may represent a viable approach for doxorubicin-resistant solid tumours as it reduces the risk of systemic toxicity
Summary
Feline injection-site sarcomas (FISS) are malignant skin tumours with a high local recurrence rate (14%–28%) [1] and metastasis risk ranging from 10% to 28% [2]. It may be used as an intermediate model between in vitro and and in vivo studies [5,10,11,12,13,14] It hasIt been successfully used used for assessing tumour progression [13], cancer cancer cell invasion and metastasis [11,12,15], proand antiangiogenic drug response [16], vascular cell invasion and metastasis [11,12,15], pro- and antiangiogenic drug response [16], vascular effects of effects of photodynamic therapy [17], toxicological and efficiency studies on anticancer drugs [13,18,19,20,21].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
